Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
Identifieur interne : 000651 ( Main/Curation ); précédent : 000650; suivant : 000652Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
Auteurs : Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2007-12-15.
English descriptors
- KwdEn :
Abstract
In a 5‐year, double‐blind study, subjects with Parkinson's disease (PD) who were randomized to initial treatment with ropinirole had a significantly lower incidence of dyskinesia compared with subjects randomized to levodopa, although Unified Parkinson's Disease Rating Scale (UPDRS) motor scores were significantly more improved in the levodopa group. Subjects who completed the original study were eligible to participate in a long‐term extension study conducted according to an open, naturalistic design and were evaluated approximately every 6 months until they had been followed for a total of 10 years. Comparing subjects randomized to initial treatment with ropinirole (n = 42) and levodopa (n = 27), the incidence of dyskinesia was significantly lower in the ropinirole group (adjusted odds ratio [OR] = 0.3; 95% confidence interval [CI]: 0.1, 1.0; P = 0.046) and the median time to dyskinesia was significantly longer (adjusted hazard ratio = 0.4; 95% CI: 0.2, 0.8; P = 0.007). The incidence of at least moderate wearing off (“off” time ≥26% of the awake day) was also significantly lower in the ropinirole group (adjusted OR = 0.3; 95% CI: 0.09, 0.03; P = 0.03). There were no significant differences in change in UPDRS activities of daily living or motor scores, or scores for the 39‐item PD questionnaire, Clinical Global Impression, or the Epworth Sleepiness Scale. Early treatment decisions for individual patients depend largely on the anticipated risk of side effects and long‐term complications. Both ropinirole and levodopa are viable treatment options in early PD. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21743
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000744
Links to Exploration step
ISTEX:1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="1"><mods:affiliation>University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><mods:affiliation>University Hospital, Toulouse, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>University Hospital, Toulouse</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D." last="Korczyn">Amos D. Korczyn</name>
<affiliation wicri:level="1"><mods:affiliation>Tel Aviv University Medical School, Ramat Aviv, Israel</mods:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Tel Aviv University Medical School, Ramat Aviv</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Jon Stoessl, A" sort="Jon Stoessl, A" uniqKey="Jon Stoessl A" first="A." last="Jon Stoessl">A. Jon Stoessl</name>
<affiliation wicri:level="1"><mods:affiliation>University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of British Columbia, Vancouver, British Columbia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name>
<affiliation wicri:level="1"><mods:affiliation>University of Alabama, Birmingham, Alabama, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Alabama, Birmingham, Alabama</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><mods:affiliation>University of Innsbruck, Innsbruck, Austria</mods:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>University of Innsbruck, Innsbruck</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="De Deyn, Peter P" sort="De Deyn, Peter P" uniqKey="De Deyn P" first="Peter P." last="De Deyn">Peter P. De Deyn</name>
<affiliation wicri:level="1"><mods:affiliation>University of Antwerp, Antwerp, Belgium</mods:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>University of Antwerp, Antwerp</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><mods:affiliation>Toronto Western Hospital, Toronto, Ontario, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Hospital, Toronto, Ontario</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1</idno>
<date when="2007" year="2007">2007</date>
<idno type="doi">10.1002/mds.21743</idno>
<idno type="url">https://api.istex.fr/document/1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1/fulltext/pdf</idno>
<idno type="wicri:Area/Main/Corpus">000744</idno>
<idno type="wicri:Area/Main/Curation">000651</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="1"><mods:affiliation>University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><mods:affiliation>University Hospital, Toulouse, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>University Hospital, Toulouse</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D." last="Korczyn">Amos D. Korczyn</name>
<affiliation wicri:level="1"><mods:affiliation>Tel Aviv University Medical School, Ramat Aviv, Israel</mods:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Tel Aviv University Medical School, Ramat Aviv</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Jon Stoessl, A" sort="Jon Stoessl, A" uniqKey="Jon Stoessl A" first="A." last="Jon Stoessl">A. Jon Stoessl</name>
<affiliation wicri:level="1"><mods:affiliation>University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of British Columbia, Vancouver, British Columbia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name>
<affiliation wicri:level="1"><mods:affiliation>University of Alabama, Birmingham, Alabama, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Alabama, Birmingham, Alabama</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><mods:affiliation>University of Innsbruck, Innsbruck, Austria</mods:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>University of Innsbruck, Innsbruck</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="De Deyn, Peter P" sort="De Deyn, Peter P" uniqKey="De Deyn P" first="Peter P." last="De Deyn">Peter P. De Deyn</name>
<affiliation wicri:level="1"><mods:affiliation>University of Antwerp, Antwerp, Belgium</mods:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>University of Antwerp, Antwerp</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><mods:affiliation>Toronto Western Hospital, Toronto, Ontario, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Hospital, Toronto, Ontario</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2007-12-15">2007-12-15</date>
<biblScope unit="volume">22</biblScope>
<biblScope unit="issue">16</biblScope>
<biblScope unit="page" from="2409">2409</biblScope>
<biblScope unit="page" to="2417">2417</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1</idno>
<idno type="DOI">10.1002/mds.21743</idno>
<idno type="ArticleID">MDS21743</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term>
<term>dopamine agonist</term>
<term>dyskinesia</term>
<term>levodopa</term>
<term>motor complications</term>
<term>ropinirole</term>
<term>treatment</term>
<term>wearing off</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In a 5‐year, double‐blind study, subjects with Parkinson's disease (PD) who were randomized to initial treatment with ropinirole had a significantly lower incidence of dyskinesia compared with subjects randomized to levodopa, although Unified Parkinson's Disease Rating Scale (UPDRS) motor scores were significantly more improved in the levodopa group. Subjects who completed the original study were eligible to participate in a long‐term extension study conducted according to an open, naturalistic design and were evaluated approximately every 6 months until they had been followed for a total of 10 years. Comparing subjects randomized to initial treatment with ropinirole (n = 42) and levodopa (n = 27), the incidence of dyskinesia was significantly lower in the ropinirole group (adjusted odds ratio [OR] = 0.3; 95% confidence interval [CI]: 0.1, 1.0; P = 0.046) and the median time to dyskinesia was significantly longer (adjusted hazard ratio = 0.4; 95% CI: 0.2, 0.8; P = 0.007). The incidence of at least moderate wearing off (“off” time ≥26% of the awake day) was also significantly lower in the ropinirole group (adjusted OR = 0.3; 95% CI: 0.09, 0.03; P = 0.03). There were no significant differences in change in UPDRS activities of daily living or motor scores, or scores for the 39‐item PD questionnaire, Clinical Global Impression, or the Epworth Sleepiness Scale. Early treatment decisions for individual patients depend largely on the anticipated risk of side effects and long‐term complications. Both ropinirole and levodopa are viable treatment options in early PD. © 2007 Movement Disorder Society</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000651 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000651 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonV1 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:1A12524988E5CA6FCBA1B2EE4BFF93BCCBF021E1 |texte= Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa }}
This area was generated with Dilib version V0.6.23. |